Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 6/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6780943 | 0.85 | PTGS2 (0.53) | SIRT1HSD17B10ALOX15HPGDTSHR | |
| SCHEMBL2747847 | 0.82 | CYP1A2 (0.67) | HSD17B10ALOX15HPGDMAPK1TSHR | |
| SCHEMBL4436794 | 0.82 | HSD17B10 (0.54) | HSD17B10ALOX15HPGDMAPK1TSHR | |
| SCHEMBL27453666 | 0.82 | PTGS2 (0.56) | SIRT1HPGDTSHRLMNAHTT | |
| SCHEMBL6942406 | 0.81 | HPGD (0.57) | HSD17B10ALOX15HPGDMAPK1LMNA | |
| SCHEMBL18010736 | 0.81 | PTGS2 (0.56) | SIRT1HPGDMAPK1TSHRLMNA | |
| Hydrochloric Acid SCHEMBL9952241 | 0.81 | CYP1A2 (0.65) | HSD17B10ALOX15HPGDMAPK1TSHR | |
| SCHEMBL14696832 | 0.81 | CYP1A2 (0.55) | SIRT1HSD17B10ALOX15HPGDMAPK1 | |
| SCHEMBL16834247 | 0.81 | HPGD (0.49) | HSD17B10ALOX15HPGDMAPK1TSHR | |
| SCHEMBL28728287 | 0.81 | CYP1A2 (0.65) | HSD17B10ALOX15HPGDMAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0657438-B1 | Method for producing 1,2-benzisothiazol-3-ones | SUMITOMO SEIKA CHEMICALS (JP) | 1997-07-30 | — | — | EP | claimed |
| US-5508416-A | HALOGENATING A 2-(ALKYLTHIO)BENZAMIDE, CYCLIZATION TO HETERO RING AND N-S LINKAGE | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1996-04-16 | — | — | US | claimed |
| EP-0657438-A2 | Method for producing alkylsulfinylbenzamides and 1,2-benzisothiazol-3-ones | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1995-06-14 | — | — | EP | claimed |
| WO-2017048954-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1954684-A2 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007058338-A9 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2007-11-01 | — | — | WO | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| WO-2007058338-A2 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-24 | — | — | WO | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-6821964-B2 | FOR PROPHYLAXIS AND THERAPY OF DISEASES ASSOCIATED WITH MONOCYTE ACCUMULATION, LYMPHOCYTE ACCUMULATION OR LEUCOCYTE ACCUMULATION | PFIZER INC | 2004-11-23 | — | — | US | disclosed |
| WO-2002064558-A2 | OXAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS CYTOKINE INHIBITORS | SANKYO COMPANY, LIMITED (JP) | 2002-08-22 | — | — | WO | disclosed |
| US-5744609-A | REACTING AN ALKYLTHIOBENZAMIDE WITH A HALOGEN IN A HETEROGENOUS SOLVENT TO GIVE ALKYLSULFURYLBENZAMIDES INTERMEDIATES; USEFUL ANTIBACTERIAL AND ANTIFUNGAL AGENT | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1998-04-28 | — | — | US | disclosed |
| US-5672751-A | TREATMENT OF A HALOBENZAMIDE WITH AN ALKANETHIOL IN THE PRESENCE OF A PHASE TRANSFER CATALYST | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1997-09-30 | — | — | US | disclosed |
| EP-0657438-B1 | Method for producing 1,2-benzisothiazol-3-ones | SUMITOMO SEIKA CHEMICALS (JP) | 1997-07-30 | — | — | EP | disclosed |
| EP-0751123-A2 | Method for producing alkylsulfinylbenzamides | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1997-01-02 | — | — | EP | disclosed |
| US-5508416-A | HALOGENATING A 2-(ALKYLTHIO)BENZAMIDE, CYCLIZATION TO HETERO RING AND N-S LINKAGE | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1996-04-16 | — | — | US | disclosed |
| EP-0657438-A2 | Method for producing alkylsulfinylbenzamides and 1,2-benzisothiazol-3-ones | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1995-06-14 | — | — | EP | disclosed |
| EP-0424194-A2 | Benzanilide derivatives and their use as anti-atherosclerotic agents | RHONE-POULENC SANTE (FR) | 1991-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | SIRT1 312/4885HSD17B10 726/4885ALOX15 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.